{"id":38879,"date":"2025-08-08T15:06:07","date_gmt":"2025-08-08T07:06:07","guid":{"rendered":"https:\/\/flcube.com\/?p=38879"},"modified":"2025-08-08T15:06:08","modified_gmt":"2025-08-08T07:06:08","slug":"tellgen-plans-acquisition-of-82-stake-in-wuhan-healthcare-biotech-for-rmb-328-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38879","title":{"rendered":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million"},"content":{"rendered":"\n<p>China-based Tellgen Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/300642:SHE\">SHE: 300642<\/a>) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.<\/p>\n\n\n\n<p><strong>Transaction Overview<\/strong><br>The acquisition is designed to complement Tellgen&#8217;s portfolio in the molecular pathology field and enhance its competitive edge in oncology diagnostics. Wuhan HealthCare Biotech specializes in Fluorescence In Situ Hybridization (FISH) and PCR molecular diagnostic technologies. The company has achieved rapid development of FISH reagents and automated detection equipment. Its product portfolio, primarily comprising FISH and PCR categories, has secured multiple Class III medical device registration certificates approved by the National Medical Products Administration (NMPA).<\/p>\n\n\n\n<p><strong>Financial Highlights<\/strong><br>Wuhan HealthCare Biotech reported an operating revenue of RMB 97.3 million and a net profit of RMB 17 million for the fiscal year 2024. The agreement includes a performance commitment requiring Wuhan HealthCare Biotech to achieve a total net profit of no less than RMB 91.5 million from 2025 to 2027. The agreement also specifies targets for accounts receivable collection. In the event of unmet commitments, the transferor will be required to provide share compensation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u900f\u666f\u751f\u547d\uff1a\u5173\u4e8e\u6536\u8d2d\u6b66\u6c49\u5eb7\u5f55\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u63a7\u80a1\u6743\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u900f\u666f\u751f\u547d\uff1a\u5173\u4e8e\u6536\u8d2d\u6b66\u6c49\u5eb7\u5f55\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u63a7\u80a1\u6743\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-fae5896c-67fb-4609-9f99-886e7d082094\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u900f\u666f\u751f\u547d\uff1a\u5173\u4e8e\u6536\u8d2d\u6b66\u6c49\u5eb7\u5f55\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u63a7\u80a1\u6743\u7684\u516c\u544a.pdf\">\u900f\u666f\u751f\u547d\uff1a\u5173\u4e8e\u6536\u8d2d\u6b66\u6c49\u5eb7\u5f55\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u63a7\u80a1\u6743\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u900f\u666f\u751f\u547d\uff1a\u5173\u4e8e\u6536\u8d2d\u6b66\u6c49\u5eb7\u5f55\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u63a7\u80a1\u6743\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fae5896c-67fb-4609-9f99-886e7d082094\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4274,4273,4275],"class_list":["post-38879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-she-300642","tag-tellgen","tag-wuhan-healthcare-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million\" \/>\n<meta property=\"og:description\" content=\"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-08T07:06:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T07:06:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million\",\"datePublished\":\"2025-08-08T07:06:07+00:00\",\"dateModified\":\"2025-08-08T07:06:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879\"},\"wordCount\":224,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0809.webp\",\"keywords\":[\"Cancer\",\"SHE: 300642\",\"Tellgen\",\"Wuhan HealthCare Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38879#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38879\",\"name\":\"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0809.webp\",\"datePublished\":\"2025-08-08T07:06:07+00:00\",\"dateModified\":\"2025-08-08T07:06:08+00:00\",\"description\":\"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38879\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0809.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0809.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38879","og_locale":"en_US","og_type":"article","og_title":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million","og_description":"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.","og_url":"https:\/\/flcube.com\/?p=38879","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-08T07:06:07+00:00","article_modified_time":"2025-08-08T07:06:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million","datePublished":"2025-08-08T07:06:07+00:00","dateModified":"2025-08-08T07:06:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38879"},"wordCount":224,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","keywords":["Cancer","SHE: 300642","Tellgen","Wuhan HealthCare Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38879#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38879","url":"https:\/\/flcube.com\/?p=38879","name":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38879#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","datePublished":"2025-08-08T07:06:07+00:00","dateModified":"2025-08-08T07:06:08+00:00","description":"China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare Biotechnology Co., Ltd. for a total consideration of RMB 328 million through a three-step transaction. In the initial phase, Tellgen will acquire a 72.8630% stake for RMB 291 million, at which point Wuhan HealthCare Biotech will become a controlled subsidiary and be consolidated into Tellgen\u2019s financial statements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38879"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38879#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","width":1080,"height":608,"caption":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0809.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38879\/revisions"}],"predecessor-version":[{"id":38884,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38879\/revisions\/38884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38883"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}